Association of serum TRAIL level with coronary artery disease

被引:50
作者
Mori, Katsuhito [1 ]
Ikari, Yuji [3 ]
Jono, Shuichi [1 ]
Shioi, Atsushi [2 ]
Ishimura, Eiji [1 ]
Emoto, Masanori [1 ]
Inaba, Masaaki [1 ]
Hara, Kazuhiro [3 ]
Nishizawa, Yoshiki [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka 5458585, Japan
[3] Mitsui Mem Hosp, Div Cardiol, Tokyo, Japan
基金
日本学术振兴会;
关键词
TRAIL; Coronary artery disease; Atherosclerosis; APOPTOSIS-INDUCING LIGAND; SMOOTH-MUSCLE-CELLS; HUMAN ENDOTHELIAL-CELLS; OSTEOPROTEGERIN LEVELS; KAPPA-B; ATHEROSCLEROSIS; EXPRESSION; PROLIFERATION; RECEPTOR; ACTIVATION;
D O I
10.1016/j.thromres.2009.11.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF ligand family, and is able to induce apoptosis in tumor cells. Emerging experimental findings suggest the involvement of TRAIL in vascular biology and atherosclerosis. However, little is known concerning the role of TRAIL in atherosclerosis in humans. We therefore examined whether serum TRAIL levels are associated with coronary artery disease (CAD). Serum TRAIL levels were measured by ELISA in 285 patients who underwent coronary angiography. Serum TRAIL level was significantly lower in patients with CAD (659.2 +/- 176.6 pg/ml) than in those without CAD (732.3 +/- 187.9 pg/ml, p = 0.0016). Next, the number of diseased vessels was used to represent the severity of CAD. Serum TRAIL levels were inversely associated with the severity of CAD (p for trend = 0.0005). In particular, TRAIL levels in patients with severe 3-vessel disease were significantly lower than those in subjects without CAD (602.9 +/- 150.0, 732.3 +/- 187.9 pg/ml, respectively; p<0.05). Multivariable logistic regression analysis revealed that serum TRAIL levels were significantly associated with the presence of CAD (odds ratio, 0.68; 95% confidence interval 0.51-0.90; p = 0.006). Serum TRAIL levels were inversely associated with the advanced CAD, suggesting that TRAIL may be useful as a biomarker of CAD severity. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:322 / 325
页数:4
相关论文
共 27 条
[1]   TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2 [J].
Alladina, SJ ;
Song, JH ;
Davidge, ST ;
Hao, CH ;
Easton, AS .
JOURNAL OF VASCULAR RESEARCH, 2005, 42 (04) :337-347
[2]   TRAIL and osteoprotegerin: a role in endothelial physiopathology? [J].
Corallini, Federica ;
Rimondi, Erika ;
Secchiero, Paola .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :135-147
[3]   Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro [J].
Corallini, Federica ;
Celeghini, Claudio ;
Rizzardi, Clara ;
Pandolfi, Assunta ;
Di Silvestre, Sara ;
Vaccarezza, Mauro ;
Zauli, Giorgio .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 212 (01) :89-95
[4]   Regulation of TRAIL-induced apoptosis by transcription factors [J].
Göke, R ;
Göke, A ;
Göke, B ;
Chen, YH .
CELLULAR IMMUNOLOGY, 2000, 201 (02) :77-82
[5]   CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death [J].
Janssen, EM ;
Droin, NM ;
Lemmens, EE ;
Pinkoski, MJ ;
Bensinger, SJ ;
Ehst, BD ;
Griffith, TS ;
Green, DR ;
Schoenberger, SP .
NATURE, 2005, 434 (7029) :88-93
[6]   Enhanced Sensitivity of G1 Arrested Human Cancer Cells Suggests a Novel Therapeutic Strategy Using a Combination of Simvastatin and TRAIL [J].
Jin, Zhaoyu ;
Dicker, David T. ;
El-Deiry, Wafik S. .
CELL CYCLE, 2002, 1 (01) :82-89
[7]   The TRAIL apoptotic pathway in cancer onset, progression and therapy [J].
Johnstone, Ricky W. ;
Frew, Ailsa J. ;
Smyth, Mark J. .
NATURE REVIEWS CANCER, 2008, 8 (10) :782-798
[8]   Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease [J].
Jono, S ;
Ikari, Y ;
Shioi, A ;
Mori, K ;
Miki, T ;
Hara, K ;
Nishizawa, Y .
CIRCULATION, 2002, 106 (10) :1192-1194
[9]   TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages [J].
Kaplan, MJ ;
Ray, D ;
Mo, RR ;
Yung, RL ;
Richardson, BC .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :2897-2904
[10]   Expression, regulation and function of trail in atherosclerosis [J].
Kavurma, Mary M. ;
Bennett, Martin R. .
BIOCHEMICAL PHARMACOLOGY, 2008, 75 (07) :1441-1450